BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38190968)

  • 1. [Can we avoid axillary lymph node dissection in patients with node positive invasive breast carcinoma?].
    Brousse S; Lafond C; Schmitt M; Guillermet S; Molière S; Mathelin C
    Gynecol Obstet Fertil Senol; 2024 Mar; 52(3):132-141. PubMed ID: 38190968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
    Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
    Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
    Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
    Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic de-escalation in breast cancer surgery].
    Bodet ML; Roosen A; Hequet D; Rouzier R
    Bull Cancer; 2021 Dec; 108(12):1145-1154. PubMed ID: 34656300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sentinel node and breast cancer: A state-of-the-art in 2019].
    Zeitoun J; Babin G; Lebrun JF
    Gynecol Obstet Fertil Senol; 2019 Jun; 47(6):522-526. PubMed ID: 30959186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study.
    Martínez M; Jiménez S; Guzmán F; Fernández M; Arizaga E; Sanz C
    Breast J; 2022; 2022():6111907. PubMed ID: 35855102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
    Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
    Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
    Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
    Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted axillary dissection after neoadjuvant systemic therapy in patients with node-positive breast cancer.
    Kanesalingam K; Sriram N; Heilat G; Ng EE; Meybodi F; Elder E; Brennan M; French J
    ANZ J Surg; 2020 Mar; 90(3):332-338. PubMed ID: 31845501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
    J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Axillary management in breast cancer: The French practice versus recommendations in the post-2011 era].
    Clavier A; Cornou C; Capmas P; Bats AS; Bensaid C; Nos C; Lécuru F; Ngô C
    J Gynecol Obstet Biol Reprod (Paris); 2016 May; 45(5):451-8. PubMed ID: 26989008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strategies in case of metastatic sentinel lymph node in breast cancer].
    Costaz H; Rouffiac M; Boulle D; Arnould L; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Vincent L; Jankowski C; Coutant C
    Bull Cancer; 2020 Jun; 107(6):672-685. PubMed ID: 31699399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
    Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
    Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study.
    Yang X; Li Y; Ren XT; Fan L; Hua B
    World J Surg Oncol; 2023 Jul; 21(1):214. PubMed ID: 37480099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
    Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
    Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De-escalation of axillary surgery in patients outside Z0011 criteria.
    Giannakou A; Gooch J; Gergelis KR; Weiss A
    Surgery; 2023 Aug; 174(2):416-418. PubMed ID: 37156648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
    Kuemmel S; Heil J; Rueland A; Seiberling C; Harrach H; Schindowski D; Lubitz J; Hellerhoff K; Ankel C; Graßhoff ST; Deuschle P; Hanf V; Belke K; Dall P; Dorn J; Kaltenecker G; Kuehn T; Beckmann U; Potenberg J; Blohmer JU; Kostara A; Breit E; Holtschmidt J; Traut E; Reinisch M
    Ann Surg; 2022 Nov; 276(5):e553-e562. PubMed ID: 33156057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
    Pinto CS; Peleteiro B; Pinto CA; Osório F; Costa S; Magalhães A; Mora H; Amaral J; Gonçalves D; Fougo JL
    Breast Cancer; 2022 Jul; 29(4):709-719. PubMed ID: 35304711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.